44
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Synthesis and analysis of Ag/olanzapine/cyclodextrin and Ag/Co/Olanzapine/cyclodextrin inclusion complex nanorods

, , , &
Pages 196-209 | Received 22 May 2023, Accepted 16 Dec 2023, Published online: 27 Dec 2023
 

ABSTRACT

Silver-cobalt nanoparticles were synthesised using a chemical reduction technique. Olanzapine-cyclodextrin inclusion complex containing Ag and Ag/Co nanoparticles was examined using UV-Visible, fluorescence, computational method, FT-IR, differential scanning colorimeter, X-RD, FE-SEM, and TEM methods. A blue-shifted absorption maximum was seen in the presence of the OP/CD inclusion complex with silver and silver/cobalt nanoparticles. Multiple emission was noted in the α-CD and β-CD. TEM images conformed the formation of nanorods in Ag/OP/CD and Ag/Co/OP/CD. The pure isolated OP drug or Ag/OP/CD and Ag/Co/OP/CD do not exhibit any antibacterial activity.

Acknowledgments

This research work was supported by the RUSA PHASE -2.0 [No. 128/A1/RUSA 2.0, Health and Environment] New Delhi, India. One of the authors, A. Mani is thankful to the RUSA, New Delhi, India, for the award of JRF fellowship.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Supplementary Material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/00319104.2023.2297223

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.